SEARCHGUIDELINESendocrinology, internal medicine

guidelines·endocrinology, internal medicine, family medicine, clinical trial·PMC10662004

Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Obesity Pillars · 5 authors, 6 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This Obesity Medicine Association Clinical Practice Statement reviews FDA-approved anti-obesity medications and investigational agents, summarizing efficacy, safety, and pharmacokinetic considerations.

Full summary

266 CHARS

This OMA Clinical Practice Statement 2022 is a narrative guideline based on published scientific citations, clinical perspectives, and peer review. Data regarding combination pharmacotherapy and post-bariatric pharmacotherapy are described as limited but supportive.

STUDY TYPE

guidelines

SPECIALTY

endocrinology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10662004

Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Obesity Pillars

READ THE FULL PAPER

ABSTRACT

Abstract Background This “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022” is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity medications and investigational anti-obesity agents in development. Methods The scientific information for this Clinical Practice Statement (CPS) is based upon published scientific citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership. Results This CPS describes pharmacokinetic principles applicable to those with obesity, and discusses the efficacy and safety of anti-obesity medications [e.g., phentermine, semaglutide, liraglutide, phentermine/topiramate, naltrexone/bupropion, and orlistat, as well as non-systemic superabsorbent oral hydrogel particles (which is technically classified as a medical device)]. Other medications discussed include setmelanotide, metreleptin, and lisdexamfetamine dimesylate. Data regarding the use of combination anti-obesity pharmacotherapy, as well as use of anti-obesity pharmacotherapy after bariatric surgery are limited; however, published data support such approaches. Finally, this CPS discusses investigational anti-obesity medications, with an emphasis on the mechanisms of action and summary of available clinical trial data regarding tirzepatide. Conclusion This “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022” is one of a series of OMA CPSs designed to assist clinicians in the care of patients with pre-obesity/obesity. Keywords: Anti-obesity medications, Investigational agents, Obesity, Semaglutide, Tirzepatide

CITATION EXPORT

Harold E Bays, Angela Fitch, Sandra Christensen et al.. Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. (2022). https://doi.org/10.1016/j.obpill.2022.100018

AUTHORS

5 · 6 CENTRES

Harold E Bays, Angela Fitch, Sandra Christensen, Karli Burridge, Justin Tondt

aLouisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, 3288 Illinois Avenue, Louisville, KY, 40213, USA
bAssistant Professor of Medicine Harvard Medical School, Co-Director Massachusetts General Hospital Weight Center, Boston, MA, USA
cIntegrative Medical Weight Management, 2611 NE 125th St, Suite 100B, Seattle, WA, 98125, USA
dEnara Health, 16501 106th Court, Orland Park, IL, 60467, USA
eGaining Health, 528 Pennsylvania Ave #708, Glen Ellyn, IL, 60137, USA
fDepartment of Family and Community Medicine, Eastern Virginia Medical School, P.O. Box 1980, Norfolk, VA, 23501, USA